Kanichi Research Services successfully secures grant funding
September 24, 2015
Kanichi Research Services Ltd would like to announce the Company has been successful in securing grant funding on the Horizon 2020 Small and Medium-sized Enterprises Instrument.
Horizon 2020 funds high-potential innovation through a dedicated SME instrument, which offers seamless business innovation support under the section Societal Challenges and the specific part Leadership in Enabling and Industrial Technologies (LEITs).
Provided with about ¤3 billion in funding over the period 2014-2020, the SME Instrument helps high-potential SMEs to develop groundbreaking innovative ideas for products, services or processes that are ready to face global market competition.
Kanichi RS Ltd a North West based Company will utilise the H2020 ¤50k phase 1 grant to further the development of the Kanichi flagship AM-SENSE diagnostic system for the diagnosis and treatment of Helicobacter Pylori (H.Pylori) leading to reduced incidence of gastric ulcers that can lead to stomach cancer.
AM-SENSE, is a novel electrochemical sensor (electrode) based Point of Care device that will measure increased levels of ammonia in breath enabling, immediate diagnosis, greater usability and significant cost reductions thereby leading to better health outcomes and contribute to the sustainability of the health care system in Europe and abroad. The technology is Proof of Concept and ready for the prototype development phase.
The AM-SENSE device is unique as it is a hand held portable system that can provide diagnostic feedback at the point of use. This is especially relevant when used in the community setting, bringing the benefit of an analytical laboratory into the hands of a clinician on-site in their own office/clinic.
In mature markets the system will provide user benefit and cost economies as well as presenting revenue generation at the point of use. In developing markets the system will provide delivery and access to patients in less developed community and rural settings. This will in effect bring the clinic to the patient which, this in turn, will result in treatment being given at the time of consultation avoiding issues with lack of attendance or compliance (follow-up) of conventional diagnosis (where this exists). The system will enable rapid penetration of the established ‘test and treat’ market; and penetration and growth of the ‘large scale screening’ market, particularly within high-risk countries. The market for such a device is global.